September 2026– date –
-
Advanced TME Models Unlock Novel Strategies for Enhanced ADC Therapy
Journal for ImmunoTherapy of Cancer USA Overview A recent study published in the Journal for ImmunoTherapy of Cancer modeled how the tumor immune microenvironment (TME) impedes the delivery and efficacy of antibody-drug conjugates (ADCs)... -
FDA Grants Fast Track Designation to Four Novel Cancer Therapeutics, Accelerating Development for Urgent Needs
Targeted Oncology USA Overview In August 2026, the U.S. FDA granted Fast Track designation to four novel oncology drugs, significantly accelerating their development and review processes. These include Erasca Inc.'s ERAS-0015 (pancreatic... -
AI and Advanced Pharma Tech Converge: Insilico’s INS018_055 Achieves Clinical Success
MDPI Switzerland Overview Artificial intelligence and machine learning are revolutionizing pharmaceutical R&D by integrating with advanced technologies like pharmacogenomics and organ-on-a-chip systems. AI-designed drugs, such as Ins... -
Unlocking TPD’s Promise: Nanomedicine and Programmable Proximity Platforms Revolutionize Degrader Delivery
MDPI Switzerland Overview Nanomedicine and programmable proximity platforms are emerging as pivotal solutions to the delivery challenges inherent in targeted protein degradation (TPD) technologies. Degrader molecules like PROTACs often f... -
Redefining Colorectal Cancer Treatment: Breakthroughs in Bispecific Antibodies and ADCs
MDPI Switzerland Overview Bispecific antibodies (bsAbs) and antibody-drug conjugates (bsADCs) are ushering in a new era for colorectal cancer (CRC) treatment, offering solutions to challenges like tumor heterogeneity and drug resistance.... -
Generative AI & Quantum Computing Converge to Revolutionize Inverse Design for Molecules and Materials
SEMICON Taiwan Taiwan Overview Generative AI is enabling a transformative "inverse design" approach, directly generating molecular and material structures with desired properties, thereby fundamentally reshaping drug discovery and materi... -
Nature Communications: AI-Powered RCDO Framework Integrates Molecular Generation and Experimental Feedback to Accelerate Drug Discovery
Nature Communications Unknown Overview A groundbreaking closed-loop reinforcement learning framework, Rapid Compound Directed Optimization (RCDO), has been unveiled in a new Nature Communications paper for drug discovery. RCDO seamlessly... -
FDA Approves Lisraya (Brepocitinib) as First Oral JAK Inhibitor for Adult Dermatomyositis, Efficacy & Safety Confirmed in Phase 3 Trial of 241 Patients
FDA USA Overview The US FDA has approved Lisraya (brepocitinib) tablets as the first oral treatment for adult dermatomyositis. Granted Orphan Drug and Priority Review designations, this JAK pathway inhibitor effectively reduces inflammat... -
Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline
Becker's Hospital Review Unknown Overview A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics' oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction i... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific...
